Astellas Pharma is digging up some cash to use one of 4D Molecular Therapeutics’ gene therapy vectors for at least one rare eye disease ... retinotropic R100 vector for one genetic target ...

underwent unilateral gene therapy with the fellow eye acting as internal control. The surgeries were uncomplicated in both cases with successful detachment of the macula by subretinal vector ...